Skip to content
← Full study record

NCT02557035 · OUTCOME

Percentage of Patients With no Emetic Episodes in the Delayed Phase

An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting · Source last updated 2018-06-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
>24-120 hours

Groups in this outcome

I.V. Palonosetron Infusion Plus Dexamethasone

Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

I.V. Palonosetron Bolus Plus Dexamethasone

Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
I.V. Palonosetron Infusion Plus Dexamethasone225
I.V. Palonosetron Bolus Plus Dexamethasone215

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
I.V. Palonosetron Infusion Plus Dexamethasone176Not reportedNot reportedNot reportedNot reported
I.V. Palonosetron Bolus Plus Dexamethasone168Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        176
      2. group Id
        OG001
        value
        168
denoms
  1. counts
    1. group Id
      OG000
      value
      225
    2. group Id
      OG001
      value
      215
    units
    Participants
groups
  1. description
    Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as an infusion with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone
    id
    OG000
    title
    I.V. Palonosetron Infusion Plus Dexamethasone
  2. description
    Intravenous palonosetron (Aloxi 0.25 mg solution for injection) as a bolus with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4. Palonosetron Dexamethasone
    id
    OG001
    title
    I.V. Palonosetron Bolus Plus Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
>24-120 hours
title
Percentage of Patients With no Emetic Episodes in the Delayed Phase
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice